Filing Details

Accession Number:
0000820081-14-000005
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-20 15:36:18
Reporting Period:
2014-02-18
Filing Date:
2014-02-20
Accepted Time:
2014-02-20 15:36:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
820081 Cambrex Corp CBM Pharmaceutical Preparations (2834) 222476135
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1227835 Gregory Sargen One Meadowlands Plaza
East Rutherford NJ 07073
Evp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-18 8,500 $13.75 41,819 No 4 M Direct
Common Stock Acquisiton 2014-02-18 30,000 $5.51 71,819 No 4 M Direct
Common Stock Disposition 2014-02-18 38,500 $21.66 33,319 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2014-02-18 8,500 $0.00 8,500 $13.75
Common Stock Stock Option (Right to Buy) Disposition 2014-02-18 30,000 $0.00 30,000 $5.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-07-26 No 4 M Direct
50,000 2015-04-23 No 4 M Direct
Footnotes
  1. The option, representing a right to purchase a total of 8,500 shares, became exercisable in four equal annual installments beginning on July 26, 2008, which was the first anniversary of the date on which the option was granted.
  2. The option, representing a right to purchase a total of 100,000 shares, became exercisable in four equal annual installments beginning on April 23, 2009, which was the first anniversary of the date on which the option was granted.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.45 to $21.86, inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.